Breaking News

Tekmira Changes Name to Arbutus Biopharma

Suspends work on Ebola, will focus on Hepatitis B drug development

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Tekmira Pharmaceuticals Corporation revealed plans to halt its work on TKM-Ebola and change its corporate name to Arbutus Biopharma Corporation. Arbutus will focus on developing a cure for chronic hepatitis B virus infection (HBV). The name change affirms the integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the goal of delivering a cure for chronic HBV. The combined entity fields the largest portfolio of HBV product candidates in the industry. Tekmira h...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters